S-Space College of Medicine/School of Medicine (의과대학/대학원) Psychiatry (정신과학전공) Journal Papers (저널논문_정신과학전공)
Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD
- Kim, Yeni; Shin, Min-Sup; Kim, Jae-Won; Yoo, Hee-Jung; Cho, Soo-Churl; Kim, Boong-Nyun
- Issue Date
- Hum Psychopharmacol Clin Exp 2009 ;24(2):95-102.
- Administration, Oral; Attention Deficit Disorder with Hyperactivity/*drug; therapy/physiopathology; Central Nervous System Stimulants/*administration & dosage; Child; Cognition Disorders/*drug therapy/etiology; Delayed-Action Preparations; Female; Humans; Linear Models; Male; Methylphenidate/*administration & dosage; Neuropsychological Tests; Reaction Time/drug effects
- OBJECTIVES: This study evaluated neurocognitive changes after switching from immediate release forms of methylphenidate (MPH-IR) to osmotic release oral system methylphenidate (OROS-MPH). METHODS: 102 children with attention-deficit/hyperactivity disorder (ADHD) participated in an open label, 28 day trial, performing neurocognitive test at baseline and at 28 days after the switch from MPH-IR to OROS-MPH. RESULTS: There were significant improvements in the commission error and the reaction time of both visual and auditory continuous performance tests (CPTs) at 28 days after switching from MPH-IR to OROS-MPH. A positive correlation was observed between the improvement in parent/caregiver-rated IOWA Conners total score (Delta IOWA) and the reduction in commission error (r = 0.3, p = 0.001) and reduction in reaction time variability (r = 0.3, p = 0.006) of visual CPT. In a linear regression model, the change in parent/caregiver-rated IOWA Conners scale total scores were significant predictors of change in commission error (beta = 0.3, p = 0.005, CI = 0.4-2.3, adjusted R(2) = 0.12) and RT variability (beta = 0.3, p = 0.004, CI = 0.5-2.4, adjusted R(2) = 0.09) of visual CPT. CONCLUSIONS: These data suggest that MPH-IR may be successfully switched to OROS-MPH treatment with associated improvements in neurocognitive performance. Large-scale controlled trials are needed to replicate these findings.
- 1099-1077 (Electronic)
- Files in This Item: There are no files associated with this item.